α-Internexin: A novel biomarker for pancreatic neuroendocrine tumor aggressiveness

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages

  Liu, Bei ^a   Tang, Laura H ^d   Liu, Zhaojun ^e   Mei, Mei ^a   Yu, Run ^f   Dhall, Deepti ^f   Qiao, Xin Wei ^a   Zhang, Tai Ping ^b   Zhao, Yu Pei ^b   Liu, Tong Hua ^b   Xiao, Yu ^b   Chen, Jie ^b   Xiang, Hong Ding ^b   Wu, Hai Yan ^a   Lu, Chong Mei ^a   Lv, Bin ^g   Zhou, Ya Ru ^h   Zhang, Ye ^c   Deng, Dajun ^e   Chen, Yuan Jia ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b Key Laboratory of High   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^h HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERNEXIN; GENOMIC DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BISULFITE SEQUENCING; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISTANT METASTASIS; DNA METHYLATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC PROCEDURES; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SPLENECTOMY; SURVIVAL RATE; SURVIVAL TIME; TUMOR AGGRESSIVENESS; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84899930202     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2874     Document Type: Article

References (46)

1. de Wilde RF, Edil BH, Hruban RH, Maitra A. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol. 2012;9:199-208.
2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469-1492.
3. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
4. Jonkers YM, Ramaekers FC, Speel EJ. Molecular alterations during insulinoma tumorigenesis. Biochim Biophys Acta. 2007;1775:313-332.
5. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753-781.
6. Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008;15:409-427.
7. ZikusokaMN,Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer. 2005;104:2292-2309.
8. Rin di G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol. 2012;8:54-64.
9. Yao JC, Hassan M, Phan A, et al. One hundred years after " carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26: 3063-3072.
10. Cupisti K, Höppner W, Dotzenrath C, et al. Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur J Clin Invest. 2000;30: 325-329.
11. Capurso G, Festa S, Valente R, et al. Molecular pathology and genetics of pancreatic endocrine tumours. J Mol Endocrinol. 2012; 49:R37-R50.
12. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) Best Pract Res Clin Endocrinol Metab. 2010 24 355-370.
13. Wang EH, Ebrahimi SA, Wu AY, Kashefi C, Passaro E Jr., Sawicki MP. Mutation of theMENINgene in sporadic pancreatic endocrine tumors. Cancer Res. 1998;58:4417-4420.
14. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998;129:484-494.
15. Jiao Y, Shi C, Edil BH, et a l. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-1203.
16. Gumbs AA, Moore PS, Falconi M, et al. Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J Surg Oncol. 2002;81:45-53; discussion 54.
17. Omary MB, Coulombe PA, McLean WH. Intermediate filament proteins and their associated diseases. N Engl J Med. 2004;351: 2087-2100.
18. Rauch U, Klotz M, Maas-Omlor S, et al. Expression of intermediate filament proteins and neuronal markers in thehumanfetal gut. J Histochem Cytochem. 2006;54:39-46.
19. Foley J, Witte D, Chiu FC, Parysek LM. Expression of t he neural intermediate filament proteins peripherin and neurofilament-66/-internexin in neuroblastoma. Lab Invest. 1994;71:193-199.
20. Näthke I. Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC. Nat Rev Cancer. 2006; 6:967-974.
21. Chen YJ, Vortmeyer A, Zhuang Z, Huang S, Jensen RT. Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res. 2003;63:817-823.
22. Mei M, Deng D, Liu TH, et al. Clinical implications of microsatellite instability and MLH1 gene inactivation in sporadic insulinomas. J Clin Endocrinol Metab. 2009;94:3448-3457.
23. Rin di G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104:764-777.
24. Deng D, Deng G, Smith MF, et al. Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. Nucleic Acids Res. 2002; 30:E13.
25. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28:245-255.
26. Nagano Y, Kim do H, Zhang L, et al. A llelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer. 2007;14:483-492.
27. Roldo C, Missiaglia E, Hagan JP, et al. M icroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24:4677-4684.
28. Speisky D, Duces A, Bièche I, et al. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. Clin Cancer Res. 2012;18:2838-2849.
29. Tang LH, Contractor T, Clausen R, et al. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res. 2012;18:4612-4620.
30. Lee J, Sung CO, Lee EJ, et al. M etastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. PLoS One. 2012;7:e34456.
31. Corbo V, Beghelli S, Bersani S, et al. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. A nn Oncol. 2012;23:127-134.
32. Ducray F, Criniè re E, Idbaih A, et al.-Internexin expression identifies 1p19q codeleted gliomas. Neurology. 2009;72:156-161.
33. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 2013;24:152-160.
34. Mokhtari K Ducray F Kros JM et al. Internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organizati on for research and treatment of cancer trial 26951 Cancer. 2011 117 3014-3026
35. Ishida M, Kushima R, Brevet M, Chatelain D, Okabe H. Co-expression of neuronal intermediate filaments, p eripherin and alphainternexin in human well-differentiated endocrine neoplasms (carcinoid tumors) of the appendix. Mol Med Report. 2008;1:191-195.
36. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer. 2005;5:223-231.
37. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999;59:2029-2033.
38. Kim S, Coulombe PA. Emerging role for the cytoskeleton as an organizer and regulator of translation. Nat Rev Mol Cell Biol. 2010; 11:75-81.
39. Herrmann H, Bär H, Kreplak L, Strelkov SV, Aebi U. Intermediate filaments: from cell architecture to nanomechanics. Nat Rev Mol Cell Biol. 2007;8:562-573.
40. Di Bella A, Regoli M, Nicoletti C, Ermini L, Fonzi L, Bertelli E. An appraisal of intermediate filament expression in adult and developing pancreas: vimentin is expressed in-cells of rat and mouse embry os. J Histochem Cytochem. 2009;57:577-586.
41. Lopez-Egido J, Cunningham J, Berg M, Oberg K, Bongcam-Rudloff E, Gobl A. Menin's interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. Exp Cell Res. 2002;278:175-183.
42. Honda K, Yamada T, Endo R, et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol. 1998;140:1383-1393.
43. Miyanaga A, Honda K, Tsuta K, et al. Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in highgrade neuroendocrine pulmonary tumours. Ann Oncol. 2013;24: 84-90.
44. Hemingway H, Croft P, Perel P, et al. Prognosis Research Strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ. 2013;346:e5595.
45. Riley RD, Hayden JA, Steyerberg EW, et al. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med. 2013;10:e1001380.
46. Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis Research Strategy(PROGRESS)3: prognostic model research.PLoS Med. 2013;10:e1001381.